Evidence map›Paper›PMID 37305656›Full record

ArticleAPL bioengineering2023

Targeting the ADPKD methylome using nanoparticle-mediated combination therapy.

Annie Trinh, Yi Huang, Hanjuan Shao, Aparna Ram, Julien Morival, Jonathan Wang, Eun Ji Chung, Timothy L Downing

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APL bioengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Annie TrinhORCID https://orcid.org/0000-0002-9320-4891
Yi HuangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID https://orcid.org/0000-0002-6418-4414
Hanjuan Shao
Aparna RamDepartment of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Julien MorivalORCID https://orcid.org/0000-0003-1252-025X
Jonathan WangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID https://orcid.org/0000-0003-3184-2705
Eun Ji Chung
Timothy L DowningORCID https://orcid.org/0000-0002-5197-3684
University of California, Irvine · USUniversity of Southern California · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · 1994 to 2025
$19.5M
NCI NIH HHS DP2 CA250382NCI NIH HHS P30 CA062203NIDDK NIH HHS DP2 DK121328
6 · The paper itself

Abstract

DNA methylation aberrancies are found in autosomal dominant polycystic kidney disease (ADPKD), which suggests the methylome to be a promising therapeutic target. However, the impact of combining DNA methylation inhibitors (DNMTi) and ADPKD drugs in treating ADPKD and on disease-associated methylation patterns has not been fully explored. To test this, ADPKD drugs, metformin and tolvaptan (MT), were delivered in combination with DNMTi 5-aza-2'-deoxycytidine (Aza) to 2D or 3D cystic

Identifiers

PMID37305656
PMCPMC10257530
OpenAlexW4380085243

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.